Prescribing Guides
Rabeprazole Prescribing Guide for Indian Clinical Practice
Rabeprazole prescribing reference for Indian clinicians covering PPI comparative pharmacology, dosing, H. pylori regimens and NEET PG high-yield points.
MedNext Editorial Team | 2026-08-01 | 8 min read
Rabeprazole Prescribing Guide for Indian Clinical Practice
Rabeprazole prescribing reference for Indian clinicians covering PPI comparative pharmacology, dosing, H. pylori regimens and NEET PG high-yield points.
Rabeprazole is a widely prescribed proton pump inhibitor in India with a pharmacokinetic profile that offers rapid onset of action and reduced dependence on CYP2C19 genetic polymorphisms compared to other PPIs.
Clinical Pharmacology Overview
Rabeprazole is a substituted benzimidazole that irreversibly inhibits the H+/K+ ATPase (proton pump) on parietal cells. Like all PPIs, it is a prodrug requiring acid activation. However, rabeprazole has the highest pKa among PPIs (approximately 5.0), meaning it converts to its active sulphenamide form faster and at a less extreme pH than omeprazole or pantoprazole.
Pharmacokinetics: Bioavailability is approximately 52%. Protein binding is 96-97%. Primarily metabolised by a non-enzymatic thioether reduction pathway, with CYP2C19 and CYP3A4 playing secondary roles. This makes it the least CYP2C19-dependent PPI. Half-life is 1-2 hours. Duration of acid suppression is 24-48 hours due to irreversible pump inhibition.
Indian Brand Names
- Razo (Dr. Reddy's)
- Rablet (Lupin)
- Happi (Zydus Cadila)
- Rabeloc (Cadila Healthcare)
- Rabicip (Cipla)
Approved Indications in Indian Clinical Practice
- Gastro-oesophageal reflux disease (GERD)
- Peptic ulcer disease (gastric and duodenal)
- H. pylori eradication (as part of combination therapy)
- NSAID-associated gastric ulcers
- Zollinger-Ellison syndrome
- Non-ulcer dyspepsia (off-label but widely used)
Dosing in Adults
GERD and peptic ulcer: 20 mg orally once daily before breakfast for 4-8 weeks.
Maintenance: 10-20 mg once daily.
H. pylori eradication: 20 mg twice daily as part of triple therapy for 14 days.
Zollinger-Ellison syndrome: 60 mg once daily initially; doses up to 100 mg/day or 60 mg twice daily may be needed.
NSAID ulcer prophylaxis: 10-20 mg once daily.
Timing: 30-60 minutes before a meal, preferably before breakfast.
Important Drug Interactions
- Clopidogrel: rabeprazole has the least interaction with clopidogrel among PPIs (similar to pantoprazole) due to minimal CYP2C19 inhibition
- Ketoconazole, itraconazole: reduced absorption due to elevated gastric pH
- Methotrexate: potential for increased methotrexate levels
- Atazanavir: reduced absorption -- avoid combination
- Warfarin: monitor INR (potential interaction)
- Iron, calcium, B12: reduced absorption with chronic use
Side Effects and Monitoring
Common: headache, diarrhoea, flatulence, abdominal pain, nausea.
Long-term: the same class effects as all PPIs -- hypomagnesaemia, B12 deficiency, increased fracture risk, C. difficile infection.
Rare: interstitial nephritis, subacute cutaneous lupus.
Monitoring: magnesium levels if on long-term therapy. B12 if symptomatic or on prolonged use. Periodic reassessment of continued PPI need.
Special Populations
Pregnancy: Category B. Limited human data. Use only if clearly needed. Omeprazole has the most pregnancy safety data among PPIs.
Renal impairment: No dose adjustment required.
Hepatic impairment: Use with caution in severe hepatic impairment. No formal dose adjustment but clearance is reduced.
Elderly: No dose adjustment. Monitor for long-term adverse effects (fractures, infections).
NEET PG High-Yield Points
- Highest pKa among PPIs (~5.0) -- fastest onset of acid suppression
- Least CYP2C19-dependent PPI -- most predictable across genetic polymorphisms
- All PPIs are prodrugs requiring acid activation in parietal cell canaliculus
- PPIs irreversibly inhibit H+/K+ ATPase -- duration exceeds plasma half-life
- PPI potency ranking (generally): esomeprazole >= rabeprazole > omeprazole > lansoprazole > pantoprazole
- Class effects: Mg deficiency, B12 deficiency, C. difficile, fractures
- Preferred (with pantoprazole) when co-prescribing clopidogrel
- Rebound acid hypersecretion on withdrawal
Indian Regulatory Status
Rabeprazole is a Schedule H drug under the Drugs and Cosmetics Act. It is included in the NLEM of India. Commonly available in FDCs with domperidone (e.g., Razo-D). The CDSCO and DCGI have periodically reviewed PPI-prokinetic FDCs for rationality. Price is regulated under DPCO for listed formulations.
Frequently Asked Questions
How does rabeprazole differ from other PPIs?
Rabeprazole has the fastest onset of acid suppression among PPIs due to its higher pKa (approximately 5.0), meaning it is activated at a slightly less acidic pH. It also has the least dependence on CYP2C19 metabolism, making its efficacy more predictable across genetic polymorphisms.
Does CYP2C19 polymorphism affect rabeprazole?
Rabeprazole is primarily metabolised by a non-enzymatic reduction pathway, with CYP2C19 playing a lesser role compared to omeprazole or pantoprazole. This means poor and extensive CYP2C19 metabolisers show less variation in drug levels with rabeprazole, making it a good choice when CYP2C19 status is unknown.
What is the dose for H. pylori eradication?
Rabeprazole 20 mg twice daily is used as part of triple therapy (with amoxicillin 1 g BD + clarithromycin 500 mg BD) for 14 days. Quadruple therapy with bismuth is used in clarithromycin-resistant areas.
Is rabeprazole available over the counter in India?
No. Rabeprazole is a Schedule H drug in India and requires a prescription. However, in practice, OTC dispensing of PPIs remains common in many pharmacies despite the regulatory requirement.
Continue reading
Prescribing GuidesMetformin Prescribing Guide for Indian Clinical Practice
Evidence-based metformin prescribing for Indian clinicians covering dosing, brands, interactions, monitoring and NEET PG high-yield points.
Prescribing GuidesCeftriaxone Prescribing Guide for Indian Clinical Practice
Complete ceftriaxone prescribing reference for Indian clinicians covering indications, dosing, reconstitution, drug interactions and NEET PG points.
Prescribing GuidesAmoxicillin Prescribing Guide for Indian Clinical Practice
Comprehensive amoxicillin prescribing reference for Indian doctors covering dosing, brands, resistance patterns and NEET PG high-yield pharmacology.
Continue with Prescribing Guides
Apply what you have read with clinical prescribing MCQs that test real decision-making: drug choice, dose selection, interactions and monitoring.
Try prescribing questionsBrowse all prescribing guides